Latigo Biotherapeutics, Inc.

Lo que declaró Latigo Biotherapeutics, Inc. el 3 de septiembre de 2026

Del propio 8-K de la empresa.

Conferencias de resultados

Latigo Biotherapeutics, Inc. no tiene ninguna transcripción de conferencia de resultados disponible.

Lo que dijo la dirección

“This has been a significant period for Latigo as we completed our upsized initial public offering, published positive onzotrigine abdominoplasty results in moderate-to-severe acute pain in The New England Journal of Medicine, and continued to advance our pipeline of innovative pain programs,”

Citado literalmente de la publicación, y mostrado solo cuando el informe lo atribuye a una persona con nombre.

Cómo reaccionó la cotización

Las publicaciones salen tras el cierre o antes de la apertura, así que el movimiento es el de la sesión siguiente.

A qué se dedica Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines. Latigo’s drug candidates are designed to rapidly and effectively stop the transmission of pain without the risk of addiction. The Company’s lead product candidate, onzotrigine (previously referred to as LTG-001) is an oral Na v 1.8 ion channel inhibitor intended to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-321 is an oral Na v 1.8 inhibitor being developed for chronic musculoskeletal pain. Additionally, Latigo is advancing research of additional Na v 1.8 inhibitors that can address alternative formulation and delivery approaches as well as other ion channel targets for the treatment of pain. Learn more at latigobio.com or follow us on LinkedIn and X .

La propia descripción de la empresa, tal como aparece al pie de la publicación.